Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
CSE Real-Time Last Sale CAD
Today's Change
Price Quote as of

Today's Trading

Day Low 0.500
Day High 0.560
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Liberty Health Sciences Inc is committed to delivering pharmaceutical-grade cannabis to patients. The company produces pharmaceutical-grade marijuana. The company is based and operates in the United States and Canada. The company generated most of its revenue from medical cannabis.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Latest Press Releases

Magic Mushroom Advocates Seek to Emulate the Rise of CBD
- PR Newswire - PRF - Thu May 7, 8:00AM CDT
PR Newswire - PRF - CMTX
Thu May 7, 8:00AM CDT
, /PRNewswire/ -- Data indicates that psychedelics are gaining popularity. For example, in 2019, the Global Drug Survey collaborated with psychedelic researchers to examine the acceptability of psychedelic products and other drugs such as MDMA (ecstasy) and ketamine in the field of psychiatry. "We found high rates of acceptance especially among those with prior experience of using them, although fears based on myths and outdated science, were evident among psychedelic-naïve respondents," the shows. Just earlier last year the U.S. Food and Drug Administration () approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Now as states begin to mull the question of psilocybin's legality, this new field of potential medicinal substances may follow a comparable pathway to legalization with the cannabis medical market. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), Liberty Health Sciences Inc. (OTC: LHSIF) (CSE: LHS), Auxly Cannabis Group Inc. (OTC: CBWTF) (TSX-V: XLY), 22nd Century Group, Inc. (NYSE: XXII), MedMen Enterprises Inc. (OTC: MMNFF) 
Liberty Health Sciences Announces Expansion of its Cannabis Brand Portfolio
- CNW Group - Fri Apr 24, 7:13AM CDT
CNW Group - CMTX
Fri Apr 24, 7:13AM CDT
Liberty's portfolio of premium products include Clarity Brands, Papa's Herb, Mary's Medicinal, G Pen, PAX, Lemon and Grass, Liberty Health Sciences, Zentient and Pretty Pistil
Liberty Health Sciences Provides Update on Recent Developments and Response to COVID-19
- PR Newswire - Tue Apr 21, 7:13AM CDT
PR Newswire - CMTX
Tue Apr 21, 7:13AM CDT
Liberty remains open, essential and 'life sustaining' with convenient online ordering, safe curbside pickup and free delivery
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.415 +32.53% increase
on 05/14/20
Period Open:0.440
Price movement based on the high, low and last over the given period.
0.590 -6.78% decrease
on 05/26/20
+0.110 (+25.00%) increase
since 04/27/20
3-Month 0.320 +71.88% increase
on 03/16/20
Period Open:0.500
Price movement based on the high, low and last over the given period.
0.610 -9.84% decrease
on 02/28/20
+0.050 (+10.00%) increase
since 02/27/20
52-Week 0.320 +71.88% increase
on 03/16/20
Period Open:0.760
Price movement based on the high, low and last over the given period.
0.820 -32.93% decrease
on 05/28/19
-0.210 (-27.63%) decrease
since 05/27/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies